Fat embolism syndrome medical therapy: Difference between revisions
No edit summary |
Feham Tariq (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
{{Fat embolism syndrome}} | {{Fat embolism syndrome}} | ||
{{CMG}} | {{CMG}} {{AE}} {{FT}} | ||
Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
Revision as of 00:08, 25 February 2018
|
Fat embolism syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Fat embolism syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Fat embolism syndrome medical therapy |
|
Risk calculators and risk factors for Fat embolism syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Feham Tariq, MD [2]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
Medical Therapy
Early immobilization of fractures and operative rather than conservative management decrease the risk of FES. Some studies have shown a benefit in steroid prophylaxis for patients at high risk for FES (closed pelvic fracture), while others have not. There is no benefit to steroids after FES has developed.